Get the insights you need to fight rare cancers more efficiently.
| This week's FierceBiotech is brought to you by Premier Research.
Trouble viewing? Click here. |
| Rare cancers account for more than 20 percent of new cancer diagnoses, underscoring the fact that developing treatments for these conditions demands expertise in both oncology and rare disease. Growing cooperation among big pharma, biotech companies, and academia and a more favorable regulatory environment are accelerating development of novel therapies.
Download the white paper from Premier Research and you’ll learn:
How new regulatory initiatives can expedite review and approval of investigative drugs Pros and cons of adaptive design The expanding importance of study committees such as institutional review boards and steering committees While the study of rare cancers poses special challenges, careful consideration of clinical trial design and regulatory pathways can help increase the likelihood of success. Get the insights you need to fight rare cancers more efficiently.
Premier Research. Built for Biotech℠
|
|
|
| Want to reach 137,000+ FierceBiotech subscribers with your own message?
Contact aalcover@fiercemarkets.com or call 202-824-5074.
About this email: In order to receive FierceBiotech for free, we ask that you accept an occasional email promotion from our sponsors. We carefully screen each promotion and never sell or give away your personal information. If you do not want to receive these messages, you can unsubscribe entirely from FierceBiotech.
Click here to unsubscribe. Refer to our Privacy Policy.
FierceMarkets, a division of Questex, LLC
1900 L St. NW Suite 400
Washington, DC 20036 |
